MyFinsight
Home
Blog
About
Contact
vnda: the balance sheet
Download
Download image
Thereafter
$70,776K
2029
$5,544K
2028
$5,544K
2027
$5,544K
2026
$5,544K
2025
$1,386K
Thereafter
$8,285K
2029
$1,463K
2028
$1,463K
2027
$1,463K
2026
$1,463K
2025
$366K
PONVORY
$94,338K
Hetlioz
$14,503K
Prepaid expenses and
other current assets
$21,161K
Inventory
$2,042K
Accounts receivable, net
$50,541K
Marketable securities
$223,730K
Cash and cash
equivalents
$70,022K
Non-current inventory and
other
$9,831K
Deferred tax assets
$103,073K
Intangible assets, net
$108,841K
Finance lease
right-of-use assets
$5,071K
Operating lease
right-of-use assets
$4,368K
Property and equipment,
net
$2,460K
Total current assets
$367,496K
Total assets
$601,140K
Total liabilities and
stockholders equity
$601,140K
Total stockholders
equity
$465,999K
Total liabilities
$135,141K
Accumulated deficit
-$253,579K
Accumulated other
comprehensive income
$540K
Additional paid-in capital
$718,979K
Other non-current
liabilities
$11,044K
Finance lease
non-current liabilities
$2,808K
Operating lease
non-current liabilities
$3,419K
Total current
liabilities
$117,870K
Common stock, 0.001 par
value 150,000,000...
$59K
Product revenue
allowances
$70,251K
Accounts payable and
accrued liabilities
$47,619K
Back
Back
Balance Sheet
source: myfinsight.com
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)